Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|February 14, 2012
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.
The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.
British Journal of Haematology|June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyIrina Amitai, Michelle Geddes, Nancy Zhu, et al.
Haematologica|August 18, 2022
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromesJennifer Teichman, Michelle Geddes, Nancy Zhu, et al.
BMC Medicine|March 3, 2022
Promoting deceased organ and tissue donation registration in family physician waiting rooms (RegisterNow-1): a pragmatic stepped-wedge, cluster randomized controlled registry trialAlvin Ho-Ting Li, Amit X Garg, Jeremy M Grimshaw, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Leukemia & Lymphoma|September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registryRena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
Eclinicalmedicine|May 30, 2023
Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trialLucy H R Whitaker, Lee J Middleton, Jane P Daniels, et al.
Trials|September 2, 2025
"SPHERE" multi-component novel psychosocial intervention for people with HIV: study protocol for a randomised controlled trialVasiliki Papageorgiou, Fiona C Lampe, Janey Sewell, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Pageof 21